The authors have no funding, financial relationships, or conflicts of interest to disclose.
Head and Neck
Simultaneous integrated boost–intensity-modulated radiotherapy in head and neck cancer
Version of Record online: 26 JUN 2013
Copyright © 2013 The American Laryngological, Rhinological and Otological Society, Inc.
Volume 123, Issue 12, pages E97–E103, December 2013
How to Cite
Franceschini, D., Paiar, F., Meattini, I., Agresti, B., Pasquetti, E. M., Greto, D., Bonomo, P., Marrazzo, L., Casati, M., Livi, L. and Biti, G. (2013), Simultaneous integrated boost–intensity-modulated radiotherapy in head and neck cancer. The Laryngoscope, 123: E97–E103. doi: 10.1002/lary.24257
- Issue online: 25 NOV 2013
- Version of Record online: 26 JUN 2013
- Accepted manuscript online: 17 JUN 2013 12:23PM EST
- Manuscript Accepted: 29 MAY 2013
- Manuscript Revised: 30 APR 2013
- Manuscript Received: 29 JAN 2013
- head and neck;
To review toxicity and outcomes in patients with head and neck cancer treated with simultaneous integrated boost–intensity-modulated radiotherapy (SIB-IMRT).
Review of experience with the SIB-IMRT technique.
Fifty patients were treated with the SIB-IMRT technique. Two possible schedules of radiation therapy (RT) were used: SIB 70 (70/60/54 in 33 fractions) and SIB 66 (66/60/54 in 33 fractions). Forty-one patients also received chemotherapy.
All but two patients completed treatment as prescribed. No G4 acute toxicity has been reported in our series. We did not observe any G3 to G4 chronic toxicity, apart from one case of cutaneous necrosis. After a median follow-up of 23.3 months (range, 1–60 months), 41 patients (82%) were alive and negative for disease, and one patient (2%) was alive with distant metastases. Eight patients (16%) died, seven because of progressive disease and one for other causes.
SIB-IMRT is a highly effective and safe technique of RT in the treatment of head and neck cancer.
Level of Evidence
4 Laryngoscope, 123:E97–E103, 2013